Drug intelligence / Profile preview

hyoscine butylbromide

Development stage
Phase 4
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Oral, Rectal, Intramuscular, Intravenous
01

Overview

Hyoscine butylbromide is an anticholinergic and antispasmodic pharmaceutical drug used to relieve pain and discomfort caused by smooth muscle spasms in the gastrointestinal tract, urinary tract, and other organs. It works primarily as a competitive antagonist at muscarinic acetylcholine receptors, leading to relaxation of smooth muscle. This action helps alleviate abdominal pain associated with conditions such as irritable bowel syndrome, diverticular disease, esophageal spasms, bladder spasms, biliary colic, and renal colic. It is also used to reduce excessive respiratory secretions at the end of life. The drug can be administered orally (tablets), rectally (suppositories), or by injection (intramuscular or intravenous)[1][2][4][5].

Brand names
BuscopanBuscapinaHyocimaxXspasHylacScopanBelloidHyoswiftHyopilSpaslin HBiscotas
Other names
hyoscine N-butylbromide
02

Targets

CHRM2 (Muscarinic acetylcholine receptor M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)Nicotinic Acetylcholine ReceptorM1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on hyoscine butylbromide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyoscine butylbromide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call